Similar articles for PMID: 31864157

Year	Number of Results
2001	1
2002	1
2007	2
2008	4
2009	1
2010	3
2012	1
2013	2
2014	4
2015	10
2016	8
2017	20
2018	22
2019	21
2020	22
2021	8
2022	5
2023	2
2024	1

1

Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).

Lecointre L, Velten M, Lodi M, Saadeh R, Lavoué V, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Martin D, Baldauf JJ, Akladios C, Ballester M. Lecointre L, et al. Eur J Obstet Gynecol Reprod Biol. 2020 Feb;245:64-72. doi: 10.1016/j.ejogrb.2019.12.001. Epub 2019 Dec 6. Eur J Obstet Gynecol Reprod Biol. 2020. PMID: 31864157

2

Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?

Solmaz U, Mat E, Dereli ML, Turan V, Peker N, Tosun G, Dogan A, Adiyeke M, Ozdemir A, Gungorduk K, Sanci M, Yildirim Y. Solmaz U, et al. J BUON. 2015 May-Jun;20(3):847-54. J BUON. 2015. PMID: 26214639 Free article.

3

Feasibility of extended cycles of neoadjuvant chemotherapy in patients with advanced ovarian cancer in terms of prognosis and surgical outcomes.

Kim NK, Suh DH, Kim K, Kim YB, No JH. Kim NK, et al. PLoS One. 2023 Apr 21;18(4):e0284753. doi: 10.1371/journal.pone.0284753. eCollection 2023. PLoS One. 2023. PMID: 37083873 Free PMC article.

4

Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?

Akladios C, Baldauf JJ, Marchal F, Hummel M, Rebstock LE, Kurtz JE, Petit T, Afors K, Mathelin C, Lecointre L, Schrot-Sanyan S. Akladios C, et al. Oncology. 2016;91(6):331-340. doi: 10.1159/000449203. Epub 2016 Oct 27. Oncology. 2016. PMID: 27784027

5

Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.

Vincent L, Jankowski C, Ouldamer L, Ballester M, Bendifallah S, Bolze PA, Akladios C, Costaz H, Lavoué V, Canlorbe G, Collinet P, Touboul C, Huchon C, Bricou A, Dridi S, Padéano MM, Bengrine L, Arnould L, Coutant C; Groupe de Recherche FRANCOGYN. Vincent L, et al. Eur J Surg Oncol. 2020 Sep;46(9):1689-1696. doi: 10.1016/j.ejso.2020.04.029. Epub 2020 Apr 24. Eur J Surg Oncol. 2020. PMID: 32417154

6

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.

Chung YS, Kim YJ, Lee I, Lee JY, Nam EJ, Kim S, Kim SW, Kim YT. Chung YS, et al. PLoS One. 2017 Sep 5;12(9):e0183754. doi: 10.1371/journal.pone.0183754. eCollection 2017. PLoS One. 2017. PMID: 28873393 Free PMC article.

7

The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.

Xu X, Deng F, Lv M, Chen X. Xu X, et al. Arch Gynecol Obstet. 2017 Feb;295(2):451-458. doi: 10.1007/s00404-016-4256-x. Epub 2016 Dec 3. Arch Gynecol Obstet. 2017. PMID: 27913927

8

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?

Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T. Yoneoka Y, et al. J Gynecol Oncol. 2019 Sep;30(5):e81. doi: 10.3802/jgo.2019.30.e81. J Gynecol Oncol. 2019. PMID: 31328461 Free PMC article.

9

Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.

Zhang J, Liu N, Zhang A, Bao X. Zhang J, et al. J Obstet Gynaecol Res. 2018 Sep;44(9):1808-1816. doi: 10.1111/jog.13710. Epub 2018 Jul 18. J Obstet Gynaecol Res. 2018. PMID: 30019801

10

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.

Park J, Eoh KJ, Nam EJ, Kim S, Kim SW, Kim YT, Lee JY. Park J, et al. Yonsei Med J. 2020 Apr;61(4):284-290. doi: 10.3349/ymj.2020.61.4.284. Yonsei Med J. 2020. PMID: 32233170 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

117 results

Results by year